Peptide library
Your guide to this compound.
The named U.S. product label is the appropriate source for its approved use, contraindications and handling. TRULANCE oral plecanatide: plasma concentrations of the drug and active metabolite were generally below quantitation at the labeled 3 mg dose, so a conventional systemic elimination half-life could not be calculated. Local gastrointestinal action does not establish systemic treatment benefit. A label extraction is not an independent appraisal of every supporting trial or approval of other products with the same ingredient.
Named U.S. product label sections assessed.
Product-specific editorial extraction. Complete clinical review and clinician sign-off remain pending; other jurisdictions are not inferred.
Editorial assessment · 2026-09-07
Adults meeting the labeled indications.
The labeled treatment addresses constipation symptoms.
Named-product label sections were expanded for pharmacokinetics, contraindications and selected handling or interaction details on September 7, 2026. This is not a complete trial-program appraisal or clinician sign-off. Other formulations, patient-specific decisions and other jurisdictions require separate assessment.
Activates intestinal guanylate cyclase-C receptors.
Activates intestinal guanylate cyclase-C receptors. This brief label snapshot does not replace age restrictions, contraindications or full safety information.
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
TRULANCE oral plecanatide: plasma concentrations of the drug and active metabolite were generally below quantitation at the labeled 3 mg dose, so a conventional systemic elimination half-life could not be calculated. Local gastrointestinal action does not establish systemic treatment benefit.
Named U.S. product only; label revision 20240404. Educational extraction, not complete clinical review.
TRULANCE: age under six years, or known/suspected mechanical gastrointestinal obstruction. Avoid use from ages six through seventeen; the approved indications are for adults.
Named U.S. product only; label revision 20240404. Educational extraction, not complete clinical review.
Primary source · Plecanatide
Catalog review date: Sep 6, 2026. This date alone does not establish independent clinical review.